Jimenez, Omar – Trademark Portfolio
Entity Type: 01
Jimenez, Omar owns a portfolio of 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as NAIL MD, NOMOSKI, DERMASANA, and PAINMD MAX. Of these, 4 are registered. The portfolio spans 5 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 16 (Paper Goods). Headquartered in Davie, FL.
#214 10200 State Road 84
Davie, FL 33324
Showing of trademarks Trademarks
Trademark Classifications
Jimenez, Omar's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Education; providing of training; entertainment; sporting and cultural activities
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Jimenez, Omar have?
Jimenez, Omar has 13 U.S. trademarks filed with the USPTO. Of these, 4 registered, 8 abandoned, 1 cancelled.
What trademark classes does Jimenez, Omar file in?
Jimenez, Omar files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 16 (Paper Goods), Class 41 (Education & Entertainment), Class 35 (Advertising & Business), Class 25 (Clothing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Jimenez, Omar's most well-known trademarks?
Jimenez, Omar's registered trademark portfolio includes well-known marks such as NAIL MD, NOMOSKI, DERMASANA, and PAINMD MAX. These are among 4 currently registered trademarks in the portfolio.
What is Jimenez, Omar's trademark registration success rate?
Jimenez, Omar has a 31% trademark registration rate, with 4 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.